Veterinary Oncology Diagnostics Market To Reach $3.45 Billion By 2030

Veterinary Oncology Diagnostics Market Growth & Trends

The global veterinary oncology diagnostics market is expected to reach USD 3.45 billion by 2030, registering a CAGR of 8.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, shifting focus on preventative animal healthcare, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

Additionally, the development of advanced veterinary cancer diagnostic tests, such as the world's first and only at-home cancer screening test by Oncotect, is creating lucrative opportunities in the veterinary oncology diagnostics market. This innovative canine cancer screening test enables early detection, improving treatment outcomes and offering peace of mind to pet owners. Oncotect, which detects the four most prevalent types of canine cancer, can be used at home or in-clinic, making it user-friendly and accessible. The rise in at-home testing solutions, coupled with clinical data supporting its accuracy, is expanding the market for veterinary oncology diagnostics, particularly by increasing accessibility for pet parents.

Furthermore, the increasing prevalence of cancer in pets is significantly driving the growth of the veterinary oncology diagnostics market. As per The Veterinary Cancer Society, Cancer is the top reason of death in 47% of canines, particularly those over 10 years old, and in 32% of felines. Around 1 in 4 dogs will experience abnormal tissue growth, or neoplasia, during their lifetime. With nearly 100 types of cancer affecting pets, a diagnosis can be overwhelming, yet advances in veterinary care have improved treatment success rates for both dogs and cats. Similarly, cancer is the leading cause of death in cats and dogs, affecting one in four dogs and one in five cats in Australia, according to a May 2024 study by the Australian Research Data Commons (ARDC). In the U.S., about 6 million pet dogs are expected to be diagnosed with cancer in 2024, creating a unique opportunity to improve cancer diagnosis for both pets and humans, as reported by The Cancer Letter Inc. Additionally, the American Veterinary Association states that one in four dogs will develop neoplasia at some point, and about half of dogs over the age of 10 will develop cancer.

 Request a free sample copy or view report summary: Veterinary Oncology Diagnostics Market Report

Veterinary Oncology Diagnostics Market Report Highlights

• By test type, the biopsy segment dominated the market with a share of 32.08% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.48% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.

• In terms of animal type, the canine segment attributed to the largest market share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.

• In terms of cancer type, the skin cancers segment accounted for the highest market share in 2024 and is expected to grow at the fastest CAGR of 8.56% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.

• By end use, the veterinary hospitals and clinics segment held the highest share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.

• By region, North America had the largest share, 53.9%, of the market in 2024 and is anticipated to grow the fastest, at 8.6%, in the coming years.

• Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

Veterinary Oncology Diagnostics Market Report Segmentation

Grand View Research has segmented the global veterinary oncology diagnostics market based on animal type, test type, cancer type, end-use, and region:

Veterinary Oncology Diagnostics Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Canine

• Feline

• Others

Veterinary Oncology Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Blood Tests

• Biopsy

• Genome Testing

• Endoscopy

• Urinalysis

• Imaging

Veterinary Oncology Diagnostics Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)

• Lymphoma

• Sarcomas

• Mammary Gland Tumors

• Skin Cancers

• Others

Veterinary Oncology Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Reference Laboratories

• Veterinary Hospitals & Clinics

Veterinary Oncology Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Rest of EU

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

  • Rest of APAC

• Latin America

  • Brazil

  • Argentina

  • Rest of LA

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Rest of MEA

List of Key Players in the Veterinary Oncology Diagnostics Market

• Zoetis

• Antech Diagnostics, Inc. (Mars Inc.)

• IDEXX Laboratories, Inc.

• Neogen Corporation

• Gold Standard Diagnostics (Eurofins Technologies)

• Embark Veterinary, Inc.

• VolitionRx Limited

• CANCAN DIAGNOSTICS

• Oncotect

• PetDx